Objective The objective of this study was to evaluate the value and necessity of pelvic CT examination in gastric cancer (GC) staging. Methods We reviewed the medical records of pathologically proved GC patients who had abdominopelvic CT examination for staging at our institution from January 2013 through July 2017. These pathology findings seen in the pelvis were classified into 2 categories as metastatic disease or not. Metastatic diseases were further categorized as isolated pelvis metastasis or not, and isolated pelvis metastasis was defined as the presence of pelvis metastasis without any other sites of metastasis on CT scan. Comparisons of incidence of pelvis metastases between patients with GC located in different stomach sites and between patients with enhanced CT and with non-enhanced CT were performed. Results A total of 202 patients with GC received abdominopelvic CT examinations at our institution during study period. 22.3% (n=45) of patients had findings in the pelvis, and the most common was ascites (8.4%, n=17). The metastatic diseases in pelvis were found in 3.5% (95%CI 0.9%-6%, n=7) of patients, including bone lesions (n=2), peritoneal thickening or nodules (n=1), lymphatic spread (n=1), intestinal wall thickening (n=1), and subcutaneous nodule (n=2). Isolated pelvis metastasis were found in 2.0% (95%CI 0.1%-3.9%, n=4) of all CT examination. The differences of incidence of pelvis metastases between patients with GC located in different stomach sites and between patients with enhanced CT and with non-enhanced CT were not significant (P=0.816, P=0.650, P=0.851). Conclusion In consideration of the limited yield of pelvic CT, health care cost, and radiation dose, the pelvic CT should not be performed routinely and should be reserved only for GC patients with suspected pelvic abnormalities.